Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Interleukin-6 polypeptide inhibitor and its application

A peptide inhibitor, interleukin technology, applied in the direction of peptides, anti-inflammatory agents, peptide/protein components, etc., to inhibit physiological or pathological effects, prevent or treat rheumatoid arthritis

Inactive Publication Date: 2014-07-16
NANTONG CHENGXIN AMINO ACID
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
Because the drug is a monoclonal antibody, it has disadvantages such as large molecular weight and antigenic reaction, which greatly limits its clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Immunoprotective effect of interleukin-6 polypeptide inhibitor 3 in collagen-induced mouse arthritis animal model

[0016] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of interleukin-6 polypeptide inhibitor 3 on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely normal control group, model control group, peptide inhibitor 3 low, middle and high dosage groups (0.4, 0.8 , 1.6 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and placing it in a refrigerator...

Embodiment 2

[0021] Protective Effect of Interleukin-6 Peptide Inhibitor 3 on In Vivo Immunoprotective Effects of Adjuvanted Rat Arthritis Animal Model

[0022] To construct an adjuvant rat arthritis animal model to study the therapeutic effect of interleukin-6 polypeptide inhibitor 3 on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, body weight 140 g-160 g, were randomly divided into 6 groups, namely normal control group, model control group, interleukin-6 peptide inhibitor 3 low, middle and high dosage groups (0.2, 0.4, 0.8 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10 mg / ml) into the left hindquarters of the rat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, and concretely relates to a polypeptide capable of inhibiting interleukin-6 and preventing and treating rheumatoid arthritis. The sequence of the polypeptide is QDNKKTGIQSTIKT which is a brand new sequence. The polypeptide can be used for treating the rheumatoid arthritis and has potential new drug exploitation values.

Description

[0001] Technical field: [0002] The invention relates to the field of medicine, in particular to an interleukin-6 polypeptide inhibitor for preventing and treating or preventing rheumatoid arthritis. [0003] Background technique: [0004] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02A61P29/00
Inventor 邢将军许刘华彭立军任世阔华俊国曹铭刘加根刘明明汪士金施新华刘伟峰严明
Owner NANTONG CHENGXIN AMINO ACID
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products